Mechanisms of endothelial dysfunction in obesity-associated hypertension

Brazilian Journal of Medical and Biological Research

Volumn 45, Issue 5, 2012, Pages 392-400

  Lobato, N S ^a,b   Filgueira, F P ^a   Akamine, E H ^a   Tostes, R C ^a   Carvalho, M H C ^a   Fortes, Z B ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

Author keywords

Endothelial dysfunction; Hypertension; Nitric oxide; Obesity; Oxidative stress; Renin angiotensin system

Indexed keywords

ENDOCANNABINOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE;

ADRENERGIC SYSTEM; AUTONOMIC NERVOUS SYSTEM; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; KIDNEY TUBULE ABSORPTION; OBESITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYMPATHETIC TONE; VASOCONSTRICTION;

EID: 84861145026     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2012007500058     Document Type: Review

References (81)

1. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 295: 1549-1555.
2. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010; 303: 235-241.
3. Yach D, Stuckler D, Brownell KD. Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nat Med 2006; 12: 62-66.
4. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world - a growing challenge. N Engl J Med 2007; 356: 213-215.
5. Schmidt MI, Duncan BB, Azevedo e Silva, Menezes AM, Monteiro CA, Barreto SM, et al. Chronic non-communicable diseases in Brazil: burden and current challenges. Lancet 2011; 377: 1949-1961.
6. Echahidi N, Mohty D, Pibarot P, Despres JP, O'Hara G, Champagne J, et al. Obesity and metabolic syndrome are independent risk factors for atrial fibrillation after coronary artery bypass graft surgery. Circulation 2007; 116: I213-I219.
7. Hall JE. The kidney, hypertension, and obesity. Hypertension 2003; 41: 625-633.
8. Rahmouni K, Correia ML, Haynes WG, Mark AL. Obesityassociated hypertension: new insights into mechanisms. Hypertension 2005; 45: 9-14.
9. Jonk AM, Houben AJ, de Jongh RT, Serne EH, Schaper NC, Stehouwer CD. Microvascular dysfunction in obesity: a potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. Physiology 2007; 22: 252-260.
10. De Petrocellis L, Di Marzo V. An introduction to the endocannabinoid system: from the early to the latest concepts. Best Pract Res Clin Endocrinol Metab 2009; 23: 1-15.
11. Pacher P, Mukhopadhyay P, Mohanraj R, Godlewski G, Batkai S, Kunos G. Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations. Hypertension 2008; 52: 601-607.
12. Villar IC, Francis S, Webb A, Hobbs AJ, Ahluwalia A. Novel aspects of endothelium-dependent regulation of vascular tone. Kidney Int 2006; 70: 840-853.
13. de Jongh RT, Serne EH, ljzerman RG, de Vries G, Stehouwer CD. Impaired microvascular function in obesity: implications for obesity-associated microangiopathy, hypertension, and insulin resistance. Circulation 2004; 109: 2529-2535.
14. Arcaro G, Zamboni M, Rossi L, Turcato E, Covi G, Armellini F, et al. Body fat distribution predicts the degree of endothelial dysfunction in uncomplicated obesity. Int J Obes Relat Metab Disord 1999; 23: 936-942.
15. Kobayasi R, Akamine EH, Davel AP, Rodrigues MA, Carvalho CR, Rossoni LV. Oxidative stress and inflammatory mediators contribute to endothelial dysfunction in high-fat diet-induced obesity in mice. J Hypertens 2010; 28: 2111-2119.
16. Ceravolo GS, Fernandes L, Munhoz CD, Fernandes DC, Tostes RC, Laurindo FR, et al. Angiotensin II chronic infusion induces B1 receptor expression in aorta of rats. Hypertension 2007; 50: 756-761.
17. Cardillo C, Campia U, lantorno M, Panza JA. Enhanced vascular activity of endogenous endothelin-1 in obese hypertensive patients. Hypertension 2004; 43: 36-40.
18. Verlohren S, Dubrovska G, Tsang SY, Essin K, Luft FC, Huang Y, et al. Visceral periadventitial adipose tissue regulates arterial tone of mesenteric arteries. Hypertension 2004; 44:271-276.
19. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006; 113: 1708-1714.
20. Akamine EH, Kawamoto EM, Scavone C, Nigro D, Carvalho MH, de Cassia AT et al. Correction of endothelial dysfunction in diabetic female rats by tetrahydrobiopterin and chronic insulin. J Vasc Res 2006; 43: 309-320.
21. Lobato NS, Filgueira FP, Akamine EH, Davel AP, Rossoni LV, Tostes RC, et al. Obesity induced by neonatal treatment with monosodium glutamate impairs microvascular reactivity in adult rats: role of NO and prostanoids. Nutr Metab Cardiovasc Dis 2011; 21: 808-816.
22. Dantas AP, Franco MC, Silva-Antonialli MM, Tostes RC, Fortes ZB, Nigro D, et al. Gender differences in superoxide generation in microvessels of hypertensive rats: role of NAD(P)H-oxidase. Cardiovasc Res 2004; 61: 22-29.
23. Serpillon S, Floyd BC, Gupte RS, George S, Kozicky M, Neito V, et al. Superoxide production by NAD(P)H oxidase and mitochondria is increased in genetically obese and hyperglycemic rat heart and aorta before the development of cardiac dysfunction. The role of glucose-6-phosphate dehydrogenase-derived NADPH. Am J Physiol Heart Circ Physiol 2009; 297: H153-H162.
24. Akamine EH, Urakawa TA, de Oliveira MA, Nigro D, de Carvalho MH, de Cassia AT et al. Decreased endotheliumdependent vasodilation in diabetic female rats: role of prostanoids. J Vasc Res 2006; 43: 401-410.
25. Traupe T, Lang M, Goettsch W, Munter K, Morawietz H, Vetter W, et al. Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression. J Hypertens 2002; 20: 2239-2245.
26. Tostes RC, David FL, Carvalho MH, Nigro D, Scivoletto R, Fortes ZB. Gender differences in vascular reactivity to endothelin-1 in deoxycorticosterone-salt hypertensive rats. J Cardiovasc Pharmacol 2000; 36: S99-S101.
27. Mather KJ, Mirzamohammadi B, Lteif A, Steinberg HO, Baron AD. Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type 2 diabetes. Diabetes 2002; 51: 3517-3523.
28. Gao YJ. Dual modulation of vascular function by perivascular adipose tissue and its potential correlation with adiposity/ lipoatrophy-related vascular dysfunction. Curr Pharm Des 2007; 13: 2185-2192.
29. Stern N, Marcus Y. Perivascular fat: innocent bystander or active player in vascular disease? J Cardiometab Syndr 2006; 1: 115-120.
30. Lohn M, Dubrovska G, Lauterbach B, Luft FC, Gollasch M, Sharma AM. Periadventitial fat releases a vascular relaxing factor. FASEB J 2002; 16: 1057-1063.
31. Gao YJ, Holloway AC, Zeng ZH, Lim GE, Petrik JJ, Foster WG, et al. Prenatal exposure to nicotine causes postnatal obesity and altered perivascular adipose tissue function. Obes Res 2005; 13: 687-692.
32. Ma L, Ma S, He H, Yang D, Chen X, Luo Z, et al. Perivascular fat-mediated vascular dysfunction and remodeling through the AMPK/mTOR pathway in high-fat diet-induced obese rats. Hypertens Res 2010; 33: 446-453.
33. Gao YJ, Takemori K, Su LY, An WS, Lu C, Sharma AM, et al. Perivascular adipose tissue promotes vasoconstriction: the role of superoxide anion. Cardiovasc Res 2006; 71: 363-373.
34. Kelley DE, Kuller LH, McKolanis TM, Harper P, Mancino J, Kalhan S. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care 2004; 27: 33-40.
35. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992; 16: 397-415.
36. Mykkanen L, Haffner SM, Ronnemaa T, Bergman RN, Laakso M. Low insulin sensitivity is associated with clustering of cardiovascular disease risk factors. Am J Epidemiol 1997; 146: 315-321.
37. Pessin JE, Saltiel AR. Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest 2000; 106: 165-169.
38. Potenza MA, Marasciulo FL, Chieppa DM, Brigiani GS, Formoso G, Quon MJ, et al. Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production. Am J Physiol Heart Circ Physiol 2005; 289: H813-H822.
39. Saad MF, Rewers M, Selby J, Howard G, Jinagouda S, Fahmi S, et al. Insulin resistance and hypertension: the Insulin Resistance Atherosclerosis study. Hypertension 2004; 43: 1324-1331.
40. Fortes ZB, Garcia LJ, Scivoletto R. Vascular reactivity in diabetes mellitus: possible role of insulin on the endothelial cell. Br J Pharmacol 1984; 83: 635-643.
41. Sartoretto JL, Melo GA, Carvalho MH, Nigro D, Passaglia RT, Scavone C, et al. Metformin treatment restores the altered microvascular reactivity in neonatal streptozotocininduced diabetic rats increasing NOS activity, but not NOS expression. Life Sci 2005; 77: 2676-2689.
42. Rastelli VM, Akamine EH, Oliveira MA, Nigro D, Passaglia RC, Carvalho MH, et al. Influence of insulin on the microvascular response to inflammatory mediators in neonatal streptozotocin diabetic rats. Inflamm Res 2005; 54: 173-179.
43. Laakso M, Edelman SV, Brechtel G, Baron AD. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest 1990; 85: 1844-1852.
44. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996; 97: 2601-2610.
45. Tirupattur PR, Ram JL, Standley PR, Sowers JR. Regulation of Na+,K+-ATPase gene expression by insulin in vascular smooth muscle cells. Am J Hypertens 1993; 6: 626-629.
46. 2+-ATPase. Am J Hypertens 1992; 5: 637-641.
47. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334: 374-381.
48. Esler M, Straznicky N, Eikelis N, Masuo K, Lambert G, Lambert E. Mechanisms of sympathetic activation in obesityrelated hypertension. Hypertension 2006; 48: 787-796.
49. Wofford MR, Anderson DC Jr, Brown CA, Jones DW, Miller ME, Hall JE. Antihypertensive effect of alpha- and betaadrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens 2001; 14: 694-698.
50. Carlyle M, Jones OB, Kuo JJ, Hall JE. Chronic cardiovascular and renal actions of leptin: role of adrenergic activity. Hypertension 2002; 39: 496-501.
51. Eikelis N, Schlaich M, Aggarwal A, Kaye D, Esler M. Interactions between leptin and the human sympathetic nervous system. Hypertension 2003; 41: 1072-1079.
52. Rahmouni K, Morgan DA, Morgan GM, Liu X, Sigmund CD, Mark AL, et al. Hypothalamic PI3K and MAPK differentially mediate regional sympathetic activation to insulin. J Clin Invest 2004; 114: 652-658.
53. Rahmouni K, Haynes WG, Morgan DA, Mark AL. Role of melanocortin-4 receptors in mediating renal sympathoactivation to leptin and insulin. J Neurosci 2003; 23: 5998-6004.
54. Bulow J, Madsen J, Astrup A, Christensen NJ. Vasoconstrictor effect of high FFA/albumin ratios in adipose tissue in vivo. Acta Physiol Scand 1985; 125: 661-667.
55. Poykko SM, Kellokoski E, Horkko S, Kauma H, Kesaniemi YA, Ukkola O. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 2003; 52: 2546-2553.
56. Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K, et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004; 43: 1318-1323.
57. Guimaraes S, Moura D. Vascular adrenoceptors: an update. Pharmacol Rev 2001; 53: 319-356.
58. Tesfamariam B, Weisbrod RM, Cohen RA. Cyclic GMP modulators on vascular adrenergic neurotransmission. J Vasc Res 1992; 29: 396-404.
59. Loesch A, Maynard KI, Burnstock G. Calcitonin gene-related peptide- and neuropeptide Y-like immunoreactivity in endothelial cells after long-term stimulation of perivascular nerves. Neuroscience 1992; 48: 723-726.
60. Coutinho GC, Durieu-Trautmann O, Strosberg AD, Couraud PO. Catecholamines stimulate the IFN-gamma-induced class II MHC expression on bovine brain capillary endothelial cells. J Immunol 1991; 147: 2525-2529.
61. Born GV. Recent evidence for the involvement of catecholamines and of macrophages in atherosclerotic processes. Ann Med 1991; 23: 569-572.
62. Rahmouni K, Mark AL, Haynes WG, Sigmund CD. Adipose depot-specific modulation of angiotensinogen gene expression in diet-induced obesity. Am J Physiol Endocrinol Metab 2004; 286: E891-E895.
63. Barton M, Carmona R, Morawietz H, d'Uscio LV, Goettsch W, Hillen H, et al. Obesity is associated with tissue-specific activation of renal angiotensin-converting enzyme in vivo: evidence for a regulatory role of endothelin. Hypertension 2000; 35: 329-336.
64. Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M, et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005; 45: 356-362.
65. Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 1981; 304: 930-933.
66. Fliser D, Dikow R, Demukaj S, Ritz E. Opposing effects of angiotensin II on muscle and renal blood flow under euglycemic conditions. JAm Soc Nephrol 2000; 11: 2001-2006.
67. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 1997; 100: 2158-2169.
68. Luscher TF. Endothelial dysfunction: the role and impact of the renin-angiotensin system. Heart 2000; 84 (Suppl 1): i20-i22.
69. Nunes VW, Fortes ZB, Nigro D, Carvalho MH, Zorn TM, Scivoletto R. Influence of enalapril on the endothelial function of DOCA-salt hypertensive rats. Gen Pharmacol 2000; 34: 117-125.
70. Watanabe S, Tagawa T, Yamakawa K, Shimabukuro M, Ueda S. Inhibition of the renin-angiotensin system prevents free fatty acid-induced acute endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol 2005; 25: 2376-2380.
71. Zhao W, Swanson SA, Ye J, Li X, Shelton JM, Zhang W, et al. Reactive oxygen species impair sympathetic vasoregulation in skeletal muscle in angiotensin II-dependent hypertension. Hypertension 2006; 48: 637-643.
72. Welch WJ. Angiotensin II-dependent superoxide: effects on hypertension and vascular dysfunction. Hypertension 2008; 52: 51-56.
73. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006; 27: 73-100.
74. Bluher M, Engeli S, Kloting N, Berndt J, Fasshauer M, Batkai S, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006; 55: 3053-3060.
75. Cote M, Matias I, Lemieux I, Petrosino S, Almeras N, Despres JP, et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes 2007; 31: 692-699.
76. Randall MD, Harris D, Kendall DA, Ralevic V. Cardiovascular effects of cannabinoids. Pharmacol Ther 2002; 95: 191-202.
77. Lake KD, Martin BR, Kunos G, Varga K. Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. Hypertension 1997; 29: 1204-1210.
78. Gardiner SM, March JE, Kemp PA, Bennett T. Complex regional haemodynamic effects of anandamide in conscious rats. Br J Pharmacol 2002; 135: 1889-1896.
79. Pacher P, Batkai S, Kunos G. Cardiovascular pharmacology of cannabinoids. Handb Exp Pharmacol 2005; 599-625.
80. Wheal AJ, Bennett T, Randall MD, Gardiner SM. Cardiovascular effects of cannabinoids in conscious spontaneously hypertensive rats. Br J Pharmacol 2007; 152: 717-724.
81. Batkai S, Pacher P, Osei-Hyiaman D, Radaeva S, Liu J, Harvey-White J, et al. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 2004; 110: 1996-2002.